Medical professionals Timothy Holtz and Teri Mills worked with AIDS patients in the 1990s, when treatments were few. With ...

The European Medicines Agency has recommended authorizing a twice-yearly injectable drug aimed at preventing HIV, which ...

CHENNAI: Gilead Sciences has achieved another milestone in its efforts to bring in a preventive drug to curb the still ...

Parents with children insured by Medicaid fear changes to the government program mean vaccines will no longer be covered.

What Happened? Shares of biopharmaceutical company Gilead Sciences (NASDAQ:GILD) jumped 3% in the afternoon session after its ...

Jeremiah Johnson, executive director of PrEP4All, an organization committed to HIV prevention and care, talks about the ...

Long-acting lenacapavir has been shown to be a promising option for HIV PrEP and is now recommended globally by WHO, with a ...

Gilead upgraded to Buy by Needham as Yeztugo gains physician favor, with sales forecast to reach $6.4 billion by 2035, ...

Four months after giving Eli Lilly’s Alzheimer’s disease treatment a thumbs-down, Europe’s Committee for Medicinal Products ...

The drug is administered subcutaneously twice a year, making it easier for high-risk patients to comply with prophylaxis.

The European Union's drugs regulator has recommended approval of Gilead Sciences' lenacapavir, a twice-yearly injection, for ...

Gilead Sciences (GILD) stock gains as Needham upgrades the company to Buy from Hold citing its new HIV prevention injectable, ...